Learn about the promising results of triplet therapy in early bladder cancer treatment, offering new hope for patients.

Discover how NCOA6 loss is associated with aggressive prostate cancer and EGFR overexpression, highlighting potential ...

Explore how private sector initiatives are supporting community oncology practices in offering clinical trials, addressing barriers to access and improving patient outcomes.

In patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) with MET overexpression and/or amplification whose disease has progressed on osimertinib (Tagrisso), adding the MET inhibitor ...

The HER2 antibody drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) significantly improved progression-free survival (PFS) compared with physician’s choice of chemotherapy in patients with ...

The novel antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) continues to show significant survival benefits for patients with EGFR mutated nonsquamous non-small cell lung cancer (NSCLC) ...

The phase 3 DeLLphi-305 trial showed tarlatamab plus durvalumab significantly improved overall and progression-free survival in extensive-stage small cell lung cancer.

The FDA granted fast track designation to investigational therapies across a range of cancer types, including lung, prostate, gastrointestinal, and urothelial cancers. Here are the highlights.

Adding the androgen receptor pathway inhibitor (ARPI) darolutamide (Nubeqa) to standard-of-care androgen deprivation therapy (ADT) and locoregional radiation therapy significantly improved ...

Once again, a major clinical trial has shown that for patients with muscle invasive bladder cancer (MIBC) who were ineligible for or decline cisplatin-based chemotherapy before radical cystectomy, ...

Sacituzumab govitecan extends survival in advanced endometrial cancer post chemotherapy and immunotherapy, per phase 3 data.

The early promise of therapeutic gold seen in clinical trials of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd; Enhertu) for HER2-low, hormone receptor (HR)-positive early-stage ...